Sophie Paget-Bailly is a research engineer in epidemiology and clinical research. She passed with honours the East of France inter-region master’s degree in public health and occupational and environmental risks. During the master’s degree’s internship in the Interregional Epidemiology Unit of Bourgogne/Franche-Comté, she realized a quantitative health risk assessment in the context of chemical contamination of groundwater. She defended a PhD in Public Health and Epidemiology in Paris XI University, Doctoral School 420, working in the Centre for Research in Epidemiology and Population Health in Villejuif, France. During her PhD, she worked on occupational exposures and head and neck cancer, providing two systematic reviews and meta-analyses and analyzing data from the ICARE case-control study. She was also representative of the PhD students at the ED420 school council.

She then joined the UMQVC at the University hospital of Besancon where she provides methodological support for clinicians in designing, analyzing and promoting results from clinical research. She is particularly involved into research on breast cancer or gynecologic cancers. She is statistical editor among the Cochrane Lung Cancer Group. She also provides lessons in biostatistics to medical school students and in research methodology to public health master’s degree students. Since 2017, she is the head of the module "Monitoring of HRQoL in clincial practice".

Main areas of expertise

  • Epidemiology
  • Clinical trials and clinical research
  • Biostatistics
  • Oncology
  • Meta-analyses and Cochrane methodology
  • Occupational epidemiology


Main ongoing external collaboration

- Cochrane Lung Cancer Group



Derniers articles

sample

PurposeThe aim of this study was to determine the prevalence of adherence to adjuvant hormonal therapy (AHT) and to...

Posté par : Dr. Amélie ANOTA, Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Breast Cancer Research and Treatment

sample

Docetaxel, cisplatin, and 5-fluorouracil (DCF) significantly improved overall survival in metastatic...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY,
Nom de la revue : Cancer Medecine

sample

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

sample

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Dr. Sophie PAGET-BAILLY, Mme. Audrey FOUBERT, Mme. Astrid POZET, Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

sample

ABSTRACTBackground: Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : The Breast

sample

La mesure de la qualité de vie relative à la santé des personnes traitées pour un cancer se développe. Ce nouvel...

Posté par : Pr. Franck BONNETAIN, Dr. Guillaume MOUILLET, Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, Mme. Ikram ES-SAAD
Nom de la revue : La revue de l'infirmière

sample

Abstract Aim: Adjuvant clinical trials in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : European Journal of Cancer

sample

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, ,
Nom de la revue : Expert Review of Anticancer Therapy

sample

AbstractBackground: Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Breast Cancer Research

sample

BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Guillaume MOUILLET, Dr. Amélie ANOTA
Nom de la revue : PlosOne

Dernières actualités

Derniers outils

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Découvrez la présentation du Pr Bonnetain dans le cadre du séminaire du Cancéropôle Ile de France sur les tumeurs...

Posté par : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN

Posté par : Mme. Astrid POZET, Mme. Joëlle FRITZSCH, Dr. Guillaume MOUILLET, Dr. Amélie ANOTA, Dr. Sophie PAGET-BAILLY

Posté par : Dr. Sophie PAGET-BAILLY

Le vendredi 17 novembre a eu lieu au PCBio du CHU de Besançon le séminaire Qualité de Vie en Cancérologie, organisé...

Posté par : Dr. Sophie PAGET-BAILLY, Mr. Ahmad OUSMEN, Dr. Guillaume MOUILLET, Mme. Joëlle FRITZSCH, Mme. Emilie CHARTON, Dr. Amélie ANOTA

2015-2018 © Copyright - UMQVC.org

Website by Pearlweb